Topic
Signatera™ Webinar: Exploring the important role of ctDNA in detecting cancer recurrence earlier

Description
Is my treatment working? Do I really have no evidence of disease?

If you have been diagnosed with colorectal cancer (CRC), you likely have many lingering questions and anxiety about cancer recurrence or whether your treatment is effective. To reduce your anxiety and answer these important questions, many patients are turning to circulating tumour DNA (ctDNA) tests. ctDNA (also known as tumor-specific DNA), are fragments of tumour DNA found in the blood and can be measured to help determine: (1) signs of cancer remaining in the body, (2) if treatment (e.g., chemotherapy) is working; (3) whether the cancer is recurring (cancer recurrence). To measure ctDNA, Natera has developed their Signatera™ test, which is a personalized, tumour-informed test – optimized to detect ctDNA. Signatera™ can identify whether cancer is still present or recurring earlier than traditional care tools.

To learn more about ctDNA and how Signatera™ can help patients through their treatments, join us on March 14th, 7:00 pm-8:00 pm (EST) for an online webinar with Dr. Michael Raphael and Dr. Minetta Liu. Dr. Raphael will provide insight into his patient’s experiences with ctDNA testing, while Dr. Liu will provide an overview of ctDNA and Signatera™.

Sign-up link: https://us06web.zoom.us/webinar/register/WN_2bdMfE2aT3KELBVmDk5Eww